Lishomwa C Ndhlovu

US Patent:

20100247521, Sep 30, 2010

Filed:

Oct 27, 2008

Appl. No.:

12/739639

Inventors:

Richard B. Jones - Toronto, CA
Mario Ostrowski - Toronto, CA
Douglas F. Nixon - San Francisco CA, US
Lishomwa C. Ndhlovu - San Francisco CA, US
James Rini - North York, CA

International Classification:

A61K 39/395
A61K 39/21
A61P 37/04
C12Q 1/02

US Classification:

4241311, 4242081, 4242071, 4241841, 435 29

Abstract:

The application relates to methods of treating chronic viral infection by modulating Tim-3 activity. In addition, the present application relates to methods of diagnosing or monitoring immune system activity or function, chronic viral infection and inflammatory disease using Tim-3 expression.

US Patent:

20180153901, Jun 7, 2018

Filed:

Mar 10, 2016

Appl. No.:

15/558178

Inventors:

- San Francisco CA, US
- Honolulu HI, US
- Takamatsu-shi, Kagawa, JP
Lishomwa Ndhlovu - Honolulu HI, US
Ravi Tandon - Honolulu HI, US
Toshiro Niki - Takamatsu-shi, Kagawa, JP
Misuomi Harashima - Takamatsu-shi, Kagawa, JP

International Classification:

A61K 31/551
A61K 38/17
A61K 45/06

Abstract:

The present invention relates to the seminal discovery of methods of using recombinant galectin proteins to reverse HIV latency. Specifically, the present invention relates to the use of recombinant galectin-9 (rGal-9) to reactivate latent HIV, wherein the HIV is hypermutated rendering the virus replication incompetent. Further, rGal-9 induces the expression of APOBEC3 cytidine deaminases and NFkB pathway components and decreases histone deacetylase (HDAC) expression.